Development of a new type of prolonged release hydrocodone formulation based on egaletspi_sup®spii_sup adprem technology using in vivo-in vitro correlation

Pharmaceutics

Volumn 3, Issue 1, 2011, Pages 73-87

  Hemmingsen, Pernille H ^a   Haahr, Anne Mette ^a   Gunnergaard, Christine ^a   Cardot, Jean Michel ^b  

^a Egalet As   (Denmark)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Abuse deterrent erodible matrix technology; Controlled release; Dissolution; Hydrocodone; IVIVC; Opioid; Oral solid dosage form; Pain management

Indexed keywords

HYDROCODONE; HYDROCODONE BITARTRATE PLUS PARACETAMOL;

ARTICLE; BIOEQUIVALENCE; BIOTECHNOLOGY; CONTROLLED RELEASE FORMULATION; CORRELATION ANALYSIS; DISPERSION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; GASTROINTESTINAL SECRETION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; SINGLE DRUG DOSE; TABLET FORMULATION; VALIDATION STUDY;

EID: 79953691833     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics3010073     Document Type: Article

References (16)

1. Homsi, J; Walsh, D.; Nelson, K.A.; Sarhill, N.; Rybicki, L.; Legrand, S.B.; Davis, M.P. A phase II study of Hydrocodone for cough in advanced cancer. Am. J. Hosp. Palliât. Care 2002,19, 49-56.
2. Homsi, J.; Walsh, D.; Nelson, K.A. Important drugs for cough in advanced cancer. Support Care Cancer 2001, 9, 565-574.
3. Palangio, M.; Wideman, G.L.; Keffer, M.; Landau, C.J.; Morris, E.; Doyle, R.T., Jr.; Jiang, J.G.; Damask, M.; de Padova, A. Dose-response effect of combination Hydrocodone with ibuprofen in patients with moderate to severe postoperative pain. Clin. Ther. 2000, 22, 990-1002.
4. Rodríguez, R.F.; Bravo, L.E.; Castro, F.; Montoya, O.; Castillo, J.M.; Castillo, M.P.; Daza, P.; Restrepo, J.M.; Rodríguez, M.F. Incidence of weak opioids adverse events in the management of cancer pain: A double-blind comparative trial. J. Palliât. Med. 2007, 10, 56-60.
5. Datamonitor DMHC2377. Commercial and Pipeline Insight: Opioids - Short acting and anti-abuse technologies set to fragment and grow the market. 2008, pub ID: DFMN1728798.
6. Labby, D.; Koder, M.; Amann, T. Opioids and Chronic Non-Malignant Pain: A Clinician's Handbook; CareOregon: Portland, OR, USA, 2003.
7. Cardot, J.-M.; Beyssac, E.; Alric, M. In vitro- in vivo correlation Importance of dissolution in IVIVC. Dissolution Techno!. 2007, 14, 15-19.
8. Cardot, J.-M.; Beyssac, E. In vitro/in vivo correlations. In Encyclopedia of Pharmaceutical Technologies, 3rd ed.; Swarbrick, J., Boylan, J.C., Eds.; Marcel Decker: Hong Kong, China, 2006; volume 1, pp. 2062-2072.
9. FDA. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System U.S.; Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER): Washington, DC, USA, 2000.
10. FDA. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations U.S.; Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER): Washington, DC, USA, 1997.
11. FDA. Guidance for Industry: Nonsterile Semisolid Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation U.S.; Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER): Washington, DC, USA, 1997.
12. FDA. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations; FDA, CDER: Washington, DC, USA, 2000.
13. Langenbucher, F. Handling of computational in vitro/in vivo correlation problems by Microsoft Excel: III. Convolution and deconvolution. Eur. J. Pharm. Biopharm. 2003a, 56, 429-437.
14. Langenbucher, F. Handling of computational IVIVC problems by Microsoft Excel: I. Principles and some general algorithms. Eur. J. Pharm. Biopharm. 2002, 53, 1-7.
15. Langenbucher, F. Handling of computational IVIVC problems by Microsoft Excel: II. Distribution functions and moments, Eur. J. Pharm. Biopharm. 2003b, 55, 77-84.
16. ® constant-release drug delivery system. Inter. J. Pharm. 2004, 281, 3-10.